News Details

View all news

Mirati Therapeutics to Commence Trading on the NASDAQ

San Diego, California, July 15, 2013

Mirati Therapeutics is focused on the development of novel therapeutics for the treatment of cancer. “Mirati” means “targeted” in Italian and reflects the new company focus: targeted therapeutics, targeted patient selection, and targeted execution that drives value. Mirati Therapeutics was created from the drug discovery foundation of MethylGene, Inc. and reshaped under the direction of a new leadership team with extensive experience in successful development and registration of targeted oncology drugs. Mirati is advancing three exciting oncology programs: MGCD265, mocetinostat and MGCD516 which were all discovered and developed internally.

The listing on the NASDAQ exchange is the culmination of a series of strategic restructuring steps to become a U.S.-based, NASDAQ-listed company with headquarters in San Diego. The changes were designed to streamline internal operations, expedite drug development activities and attract additional key talent as well as improve the investment profile of the Company by exposing Mirati Therapeutics to the broader U.S. capital markets.

“The initiation of trading of Mirati stock on the NASDAQ exchange represents a critical milestone for the Company”, said Dr. Charles Baum, President and Chief Executive Officer of Mirati Therapeutics. “With increased visibility to a much wider investor base, as well as greater liquidity and efficiency in trading on the NASDAQ, Mirati is now better positioned to see the promise of MGCD265, mocetinostat and MGCD516 translate into significant new medicines to address the unmet needs of cancer patients”.

Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our highly targeted clinical development programs are focused on treating selected tumor types that express high levels or key driver mutations of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma and MGCD516, a unique kinase inhibitor with a distinct target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics shares are traded on the NASDAQ (symbol MRTX) and the Toronto Stock Exchange (symbol MYG).

Notice to Investors

This news release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities.

Investor Relations Contacts

Mark J. Gergen
Executive Vice President & COO
Mirati Therapeutics, Inc.
Tel.: 858.535.2075

Michael Wood
Managing Director
LifeSci Advisors
Tel.: 646.597.6983

Tracey Rowlands, PhD
Director of Investor Relations and Business Development
Mirati Therapeutics, Inc.
Tel.: 514.337.3333 ext. 512

Categories: Press Releases
View all news